Scarica l'app Stockscreener
0.1668
1.88%
-0.00335
Precedente Chiudi:
$0.1701
Aprire:
$0.172
Volume 24 ore:
4.47M
Relative Volume:
0.17
Capitalizzazione di mercato:
$81.54M
Reddito:
$55.54M
Utile/perdita netta:
$-180.40M
Rapporto P/E:
-0.2117
EPS:
-0.7877
Flusso di cassa netto:
$-170.32M
1 W Prestazione:
+7.89%
1M Prestazione:
-18.63%
6M Prestazione:
-60.72%
1 anno Prestazione:
-93.05%
Intervallo 1D:
$0.164
$0.1733
Intervallo di 1 settimana:
$0.1457
$0.2137
Portata 52W:
$0.1138
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Nome
Gossamer Bio Inc
Settore
Industria
Telefono
(858) 684-1300
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.1668 | 76.99M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
542.68 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.76 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.30 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.02 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.40 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2025-07-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-05 | Ripresa | Wedbush | Outperform |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-03-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-12-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | JP Morgan | Neutral |
| 2022-09-19 | Iniziato | Wedbush | Outperform |
| 2022-04-18 | Iniziato | Raymond James | Outperform |
| 2022-04-06 | Iniziato | UBS | Buy |
| 2022-01-10 | Aggiornamento | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Ripresa | Piper Sandler | Overweight |
| 2020-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-30 | Iniziato | Berenberg | Buy |
| 2019-03-05 | Iniziato | Barclays | Overweight |
| 2019-03-05 | Iniziato | BofA/Merrill | Buy |
| 2019-03-05 | Iniziato | Evercore ISI | Outperform |
| 2019-03-05 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
Gossamer Bio (NASDAQ:GOSS) Funding Move Signals Biotech Shift - Kalkine Media
Gossamer Bio Secures Up To $250 Million To Fund Seralutinib Through Potential FDA Approval - Pulse 2.0
Latham Advises Gossamer Bio on Structured Private Placement - Latham & Watkins LLP
Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital - Legal Desire
Gossamer Bio Slips as $250M Financing Hinges on FDA ApprovalGossamer Bio (NASDAQ:GOSS) - Benzinga
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Chall - GuruFocus
Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio Secures Up to $250M to Advance Seralutinib Toward FDA Approval - citybiz
$Gossamer Bio (GOSS.US)$ yessir 🦁 mode still early - Moomoo
Gossamer Bio (GOSS) Raises $250M in Private Placement Amid Challenging Valuation Landscape - GuruFocus
Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell - marketscreener.com
Gossamer Bio secures up to $250m in milestone-based financing - Investing.com
$Gossamer Bio (GOSS.US)$ @traderslink_this_guy@TradersLink__ we never lacking 🤷♂️ 😉 - Moomoo
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval - Yahoo Finance
Gossamer Bio, Inc. announced that it expects to receive $250 million in funding - marketscreener.com
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Revenue per share of Gossamer Bio, Inc. – HAM:4GB - TradingView
Gossamer Bio achieves exceptional financial eff... - Pluang
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib - Yahoo Finance
GOSS Maintained by Piper Sandler -- Price Target Lowered to $4.0 - GuruFocus
Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates - Stocktwits
GOSS|Gossamer Bio Inc|Price:0.154|Chg%:-0.016 - TradingKey
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
$Gossamer Bio (GOSS.US)$ This is the bottom - Moomoo
Gossamer Bio: Q2 Earnings Snapshot - AOL.com
Gossamer Bio Q2 Results: EPS beats estimate, sales up 78% vs view - scanx.trade
Is Gossamer Bio Inc (GOSS) Undervalued After Q2 Earnings Beat? G - GuruFocus
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary - TradingView
Gossamer Bio reports Q2 2026 net income of $16.9M; cash $57.0M, NDA submission for seralutinib on track - TradingView
Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain - Stock Titan
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Company Profile & Introduction - Moomoo
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm - Morningstar
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio - The National Law Review
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
gossamer bio inc. Earnings dates - RTTNews
Gossamer Bio Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update - Yahoo Finance
BlackRock (GOSS) discloses 4.89M-share, 1% beneficial stake in Gossamer Bio - Stock Titan
$Gossamer Bio (GOSS.US)$ call me crazy but atlease you calling... - Moomoo
GOSS Upgraded by Leerink Partners -- Rating Changed to Outperform - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Leerink Partners Upgrades Gossamer Bio to Outperform From Market Perform, $1 Price Target - marketscreener.com
Leerink upgrades Gossamer Bio stock rating on FDA feedback By Investing.com - Investing.com UK
Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle - TechStock²
Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment - Moomoo
Gossamer Bio Inc Azioni (GOSS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):